Regorafenib: all 198 studies that test it

Page 2 of 2. Open to participants first (39), then studies with results posted, then the rest; newest registration first within each.

• KN046 Plus Regorafenib or Apatinib in MSI-H Digestive System Cancers Resistant to PD-1/PD-L1 BlockadeActive, not recruitingNCT06099821Phase 2
• Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM PatientsCompletedNCT06095375Phase 1
• Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.Active, not recruitingNCT06087263Phase 2
• Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal CancerTerminatedNCT06006923Phase 2
• Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME)WithdrawnNCT05900648Phase 2
• The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver MetastasesStatus unknownNCT05877001Phase 2
• Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing SarcomaActive, not recruitingNCT05830084Phase 1
• A Study of Cadonilimab Combined With Regorafenib in Patients With Advanced HCCCompletedNCT05773105Phase 1/2
• Chidamide + Regorafenib in Hepatocellular Carcinoma (HCC)TerminatedNCT05770882Phase 1/2
• Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior ChemotherapyActive, not recruitingNCT05672316Phase 1/2
• A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular CarcinomaActive, not recruitingNCT05644379Phase 1
• Dose-escalation of Regorafenib in Advanced Hepatocellular CarcinomaActive, not recruitingNCT05622136Phase 2
• Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver MetastasisStatus unknownNCT05524155Phase 2
• Regorafenib in Patients With Refractory Primary Bone TumorsCompletedNCT05395741Phase 1/2
• Clinical Study of Regorafenib and Nivolumab Plus ChemotherapyCompletedNCT05394740Phase 1/2
• A Clinical Trial of Regorafenib in Patients With Pretreated Advanced MelanomaActive, not recruitingNCT05370807Phase 2
• Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCCStatus unknownNCT05134532Phase 2
• A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal CancerStatus unknownNCT05130021Phase 2
• Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenibCompletedNCT04874207Phase 4
• SARC038: Phase 2 Study of Regorafenib and Nivolumab in OsteosarcomaActive, not recruitingNCT04803877Phase 2
• PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse SequenceCompletedNCT04787341Phase 2
• The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract CancersActive, not recruitingNCT04781192Phase 1/2
• A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric CancerActive, not recruitingNCT04757363Phase 2
• Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCCStatus unknownNCT04718909Phase 2
• Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal CancerCompletedNCT04534218Phase 2
• Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal CancerActive, not recruitingNCT04503694Phase 2
• Optimization for Regorafenib in HCCTerminatedNCT04476329Phase 2
• Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal CancerTerminatedNCT04450836Phase 2
• Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal CancerCompletedNCT04362839Phase 1
• Combination of Regorafenib and Nivolumab in Unresectable Hepatocellular CarcinomaCompletedNCT04310709Phase 2
• A Study of CS1001 in Combination With Regorafenib in Patients With Advanced or Refractory Solid TumorsCompletedNCT04200404Phase 1/2
• Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)CompletedNCT04170556Phase 1/2
• Regorafenib Plus PD-1 Inhibitor in Patients With Colorectal CancerStatus unknownNCT04110093Phase 1/2
• Regorafenib in Bevacizumab Refractory Recurrent GlioblastomaCompletedNCT04051606Phase 2
• Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal CancerStatus unknownNCT04030260Phase 2
• Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal CancerStatus unknownNCT04008511Phase 1/2
• JS001 Combined With Regorafenib in Patients With Advanced Colorectal CancerStatus unknownNCT03946917Phase 1/2
• Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
• Phase II Study of Regorafenib as Maintenance TherapyCompletedNCT03793361Phase 2
• Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal AdenocarcinomasTerminatedNCT03722108Phase 1/2
• Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal CancerCompletedNCT03712943Phase 1
• Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRICompletedNCT03698253Not applicable
• Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric CancerCompletedNCT03627728Phase 2
• Regorafenib in Indian Patients With Metastatic Colorectal Cancer (mCRC).CompletedNCT03564938Phase 4
• Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCCCompletedNCT03347292Phase 1
• Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard TherapyCompletedNCT03305913Phase 1
• Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal CancerCompletedNCT03081494Phase 1
• Study of Regorafenib in Patients With Advanced Myeloid MalignanciesCompletedNCT03042689Phase 1
• An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of RuxolitinibActive, not recruitingNCT02955940Phase 2
• Regorafenib in Relapsed GlioblastomaCompletedNCT02926222Phase 2
• Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal CancerTerminatedNCT02910843Phase 1
• Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTsCompletedNCT02889328Phase 2
• Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRCCompletedNCT02835924Phase 2
• The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of RegorafenibCompletedNCT02800330Phase 4
• A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal CancerStatus unknownNCT02773524Phase 3
• Use of Regorafenib in Recurrent Epithelial Ovarian CancerCompletedNCT02736305Phase 2
• Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With RegorafenibCompletedNCT02699073Phase 2
• A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon CancerTerminatedNCT02664077Phase 3
• Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GISTCompletedNCT02638766Phase 2
• Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal CancerStatus unknownNCT02619435Phase 2
• Regorafenib in GIST With Secondary C-KIT Exon 17 MutationCompletedNCT02606097Phase 2
• REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological ProgressionCompletedNCT02584465Phase 2
• Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line TherapyStatus unknownNCT02501551Phase 2
• Study of Regorafenib and Sildenafil for Advanced Solid TumorsCompletedNCT02466802Phase 1
• Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal CancerCompletedNCT02465502Phase 2
• Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer PatientsWithdrawnNCT02439723Phase 1
• Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOXTerminatedNCT02425683Phase 2
• Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric CarcinomaCompletedNCT02406170Phase 1/2
• Regorafenib Phase I Study in Mainland Chinese PatientsCompletedNCT02398513Phase 1
• A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone SarcomasCompletedNCT02389244Phase 2
• Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract CancerCompletedNCT02386397Phase 1/2
• A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)Active, not recruitingNCT02365441Phase 2
• Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard TherapyCompletedNCT02307500Phase 2
• Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent TreatmentWithdrawnNCT02287727Phase 2
• Regorafenib + Panitumumab for Colorectal CancersTerminatedNCT02199223Phase 1
• Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus BevacizumabTerminatedNCT02175654Phase 2
• Safety Study of Regorafenib With PF-03446962 to Treat Colorectal CancerCompletedNCT02116894Phase 1
• Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.CompletedNCT02106845Phase 1
• Regorafenib and Cetuximab in Patients With Advanced MalignancyCompletedNCT02095054Phase 1
• Effect of Neomycin on the Pharmacokinetics of RegorafenibCompletedNCT02001909Phase 1
• Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal CancerCompletedNCT01996969Not applicable
• Safety and Pharmacokinetics of Regorafenib and Cetuximab in CombinationCompletedNCT01973868Phase 1
• Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover BiomarkersStatus unknownNCT01949194Phase 2
• Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)CompletedNCT01929616Phase 2
• Phase II Study of Regorafenib in Metastatic Soft Tissue SarcomaCompletedNCT01900743Phase 2
• Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal CancerCompletedNCT01875380Phase 2
• Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard TherapyCompletedNCT01853319Phase 3
• Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus FluoropyrimidinesWithdrawnNCT01786538Phase 3
• Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard TherapyCompletedNCT01584830Phase 3
• Open Label Regorafenib Study to Evaluate Cardiovascular Safety Parameters, Tolerability, and Anti-tumor ActivityCompletedNCT01339104Phase 1
• Effect of Ketoconazole on Regorafenib (BAY73-4506) PharmacokineticsCompletedNCT01318265Phase 1
• Clinical Evaluation - A Phase IIA Proof of Concept Study of Regorafenib (Bayer 73-4506) in Biopsy-amenable Asian Colorectal Cancer PatientsStatus unknownNCT01189903Phase 2/3
• Determination of Safety, Efficacy, and Pharmacokinetics of "Regorafenib" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung CancerTerminatedNCT01187615Phase 1
• Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid TumorsCompletedNCT01096030Phase 1
• Safety Study of BAY73-4506 in Patients With Hepatocellular CarcinomaCompletedNCT01003015Phase 2
• The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of RegorafenibCompletedNCT01002378Phase 1
• Phase I Study to Investigate Pharmacokinetics and Safety of BAY73-4506 in Asian (Japanese) Patients With Solid Tumors.CompletedNCT00960258Phase 1
• Study to Determine Safety, Pharmacokinetics, Pharmacodynamics of BAY73-4506 in Combination With mFOLFOX6 or FOLFIRICompletedNCT00934882Phase 1

← Regorafenib overview